Rodger D. Curren, PhD

Rodger D. CurrenChief Executive Officer and Chairman of the Board

Dr. Rodger Curren co-founded IIVS and currently serves as CEO and Chairman of the Board of Directors.

After more than 10 years of specializing in genetic toxicology and chemical carcinogenesis, Dr. Rodger D. Curren created an In Vitro Toxicology Division as part of the contract research organization Microbiological Associates (now BioReliance) in 1988. This activity was subsequently incorporated as its own non-profit Institute, the Institute for In Vitro Sciences, Inc. (IIVS) in 1997. The goal was — and still is — to provide educational and laboratory-based resources for non-animal safety testing to industry, government, and animal welfare organizations, as well as the general public.

In addition to Dr. Curren’s work with IIVS, he serves on many national and international committees and science advisory boards of organizations focused on the development, validation, and practical use of alternative methods to whole animal testing. Among other activities, he is past president of the American Society for Cellular and Computational Toxicology (ASCCT), and a former member of both the Scientific Advisory Committee for the European Center for the Validation of Alternative Methods (ECVAM) and the Scientific Advisory Committee for Alternative Toxicological Methods in the U.S. He currently serves on the Advisory Boards of the Center for Responsible Science and the International Foundation for Ethical Research.

Dr. Curren’s efforts in optimizing and promoting new alternative methods have earned him several honors in the in vitro field, including the Russell and Burch Award, the Bjorn Ekwall Memorial award, and the William and Eleanor Cave award for outstanding achievements in the development, validation and advancement of humane alternatives for product testing.

Dr. Curren received his B.S. (Biology) from Purdue University, followed by an M.S. from Ohio University and a Ph.D. in microbial genetics from the Institute of Microbiology at Rutgers University. His post-doctoral work (human cell mutagenesis and DNA repair) was conducted at the Michigan Cancer Foundation and Michigan State University.

Erin H. Hill

Erin H. HillPresident

Ms. Hill co-founded IIVS in 1997 with Dr. Rodger Curren where she is currently President and a member of the Board of Directors. As President, Ms. Hill is responsible for planning, directing and coordinating activities to achieve IIVS’ mission of increasing the use and acceptance of in vitro methods. She also interacts with other groups, both domestic and international, who are involved the advancement of non-animal alternative methods with the intent of coordinating efforts leading to the regulatory acceptance of these methods.

Prior to co-founding IIVS, Ms. Hill worked for a tissue engineering company (Advanced Tissue Sciences) where she assisted with the marketing and sales of 3-Dimensional human skin constructs to the personal care and household products market. Ms. Hill then expanded her interest in in vitro methods during work for a developer of hollow fiber bioreactors for the production of mono clonal anti-bodies. In 1995 she joined the In Vitro Toxicology Unit at Microbiological Associates with Dr. Rodger Curren.

In 2010 Erin co-founded the American Society for Cellular and Computation Toxicology (ASCCT) where she serves as Treasurer. She is also a board member of the In Vitro Testing Industrial Platform. Erin received her bachelor’s degree in 1990 in Cell Biology and Biochemistry from the University of California, San Diego.

Hans A. Raabe, MS

Hans RaabeChief Operating Officer and Treasurer

As Vice President and Chief Operating Officer, Mr. Raabe is responsible for the development, design, operation and improvement of the systems that create and deliver in vitro testing services. Mr. Raabe has served as an expert on several OECD Test Guideline panels, has been an invited presenter at ICCVAM Workshops and review panels, and has participated in multiple ECVAM and ICCVAM validation studies.

Mr. Raabe joined the newly-formed IIVS in 1997 as Study Director for GLP-compliant ocular and dermal irritation assays. Prior to joining IIVS, Mr. Raabe worked for Microbiological Associates, Inc. (now BioReliance Corp.) in the Genetic Toxicology Division where he conducted and supervised in vitro and in vivo toxicity and DNA damage detection assays.

His research interests include modeling ocular and dermal irritation and wound healing events in vitro using complex 3-D tissue constructs and ex vivo tissues. He has been an SOT member since 2008.

Mr. Raabe received his BS degree in Zoology from the University of Maryland in 1984 and a MS in Biotechnology Management at the University of Maryland, University College in 1996.

Amanda K. Ulrey, RQAP-GLP

Vice President, Business Operations

Ms. Ulrey previously served as Director of Quality and Compliance for IIVS, assuming responsibility for instituting and fostering a culture of quality management and compliance throughout the organization. She provides leadership, training, and oversight of the Quality Assurance Unit, and institutes and maintains policies and procedures for regulatory compliance and organizational quality management.

Ms. Ulrey is a member of the Society of Quality Assurance (where she is currently a member of the Mentoring Program Committee, Computer Validation Initiative Committee, and GLP Specialty Section) and the American Society for Quality. She has given several presentations and authored posters on the topics of the application of GLPs to in vitro studies and the importance of supplier qualification programs.

Holger P. Behrsing, PhD

Principal Scientist
Director – Respiratory Toxicology

Bringing 20 years of experience in in vitro toxicology and expertise in the use of models for pulmonary toxicology, Dr. Behrsing conducts and oversees IIVS laboratory studies, as well as teaches and serves as an industry resource for workshops, webinars, and other educational activities. He serves as the Principal Investigator for the respiratory toxicology workshop series.

Dr. Behrsing attended the University of California at Santa Barbara for his undergraduate degree, majoring in both Biology and German Studies. He completed his Doctoral degree in Pharmacology and Toxicology at University of California Davis. He has spoken at internationally-recognized meetings and has experience with numerous in vitro and ex vivo models systems, with a well-documented background in the use of pulmonary models.

Dr. Behrsing’s CV

Gertrude-Emilia Costin, PhD, MBA, ATS, ERT

Director of Laboratory Services
Study Director, Dermal Safety & Efficacy Assessment

Dr. Costin joined IIVS in 2007 and currently oversees a wide range of safety and efficacy commercial studies and research projects using in vitro testing strategies. Her primary area of expertise is in the use of in vitro test methods for the dermal safety assessment of ingredients and final formulations manufactured by cosmetic, personal care or pharmaceutical industry, or products to be registered under US Environmental Protection Agency (EPA) the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). She also specializes in the use of non-animal methods to address the safety assessment of feminine care products or medical devices registered under the Food and Drug Administration (FDA). In addition, Dr. Costin promotes the use of in vitro efficacy assays to support anti-inflammatory or skin lightening claims of actives or finished products.

Dr. Costin is heavily involved with IIVS educational workshops on non-animal research and in vitro assay systems. In addition, she is the coordinator of the review process for the Alternatives Research Grants, awarded annually by the Alternative Research and Development Fund (ARDF), serves as Board member and Newsletter Editor for the National Capital Area Chapter of Society of Toxicology (NCAC-SOT) and the PanAmerican Society for Pigment Cell Research (PASPCR), and is a Board Council member of the American Society for Cellular and Computational Toxicology (ASCCT).

Dr. Costin received her PhD (Cum laude) from the Institute of Biochemistry of the Romanian Academy, followed by postdoctoral training at the National Cancer Institute, National Institutes of Health (NIH). Prior to joining IIVS, Dr. Costin worked as Senior Research Scientist for Avon Products, Inc. – Global R&D.

Dr. Costin’s CV

Brent Gilbert, M.Tox, MBA

Brent Gilbert, M.Tox, MBA – Business Development Manager

Mr. Gilbert joined IIVS in 2017 as our Business Development Manager bringing with him more than 15 years of experience working with Contract Research Organizations. Twelve of those years have been spent in the field of in vitro toxicology. Brent has worked with clients in the US ranging in size from small start-up organizations to Fortune 100 companies and has also established himself with a broad international client base as well.

Brent received his B.S. in Microbiology with a certificate in Biotechnology from the University of Rochester, an MBA from the University of Delaware and a Master of Toxicology from North Carolina State University. Brent is an Associate Member of the Society of Toxicology and maintains business-level proficiency in German.

G. Frank Gerberick, PhD

Chief Scientific Advisor

Dr. G. Frank Gerberick is an independent consultant and owner of GF3 Consultancy, LLC. He was employed at the Procter & Gamble Company from 1986 – 2018. Prior to joining P&G, he was a postdoctoral fellow at The Johns Hopkins School of Medicine working in the field of pulmonary immunology. While at P&G, Dr. Gerberick focused his career working in the field of dermatotoxicology. In 2004, he was appointed to the Procter & Gamble Victor Mills Society which is the highest technical honor for P&G scientists.

Dr. Gerberick’s primary research focus has been in the field of skin allergy, although he has also been active in the field of phototoxicology.He has over 175 publications and has co-authored a book entitled Toxicology of Contact Dermatitis. His laboratory’s research was focused primarily on elucidating the chemical, cellular and molecular mechanisms underlying skin allergy in hope of developing in vitro test methods for skin sensitization testing.

Dr. Gerberick was also active in research efforts in the area of respiratory allergy and understanding the role of the microbiome in human health. In the past, his laboratory was actively involved in the development and validation of the LLNA. For his effort, he was a co-recipient of two prestigious international awards: the SmithKline Beecham Laboratory Animal Welfare Prize and the Society of Toxicology’s Animal Welfare Award. He was also awarded the William and Elenor Cave Award and Lush Black Box Prize for advancing skin sensitization alternatives.

The Direct Peptide Reactivity Assay developed in Dr. Gerberick’s laboratory has been successfully evaluated by the European Union Reference Laboratory for Alternatives to Animal Testing and adopted as OECD test guideline. Finally, he was selected as the 2017 Alexander A. Fisher Lecturer which is the highest honor given by the American Contact Dermatitis Society.